You are here

  • Home
  • Archive
  • Volume 92, Issue 2
  • Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability

Article info

Article menu
Download PDFPDF
Letter
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability

Authors

  1. Correspondence to Dr Larissa Mulka, Department of Sexual Health and HIV, Royal Sussex County Hospital, Brighton, East Sussex BN2 5BE, UK; larissa.mulka{at}bsuh.nhs.uk
View Full Text

Citation

Mulka L, Annandale D, Richardson C, et al
Raltegravir-based HIV postexposure prophylaxis (PEP) in a real-life clinical setting: fewer drug–drug interactions (DDIs) with improved adherence and tolerability
Sexually Transmitted Infections 2016;92:107.

Publication history

  • Received August 4, 2015
  • Accepted August 6, 2015
  • First published February 18, 2016.
Online issue publication 
May 13, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/